Äèñêóññèîííûé Êëóá

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Àêóøåðñòâî è ãèíåêîëîãèÿ > Èíôåêöèè ïîëîâûõ ïóòåé è âîñïàëèòåëüíûå çàáîëåâàíèÿ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 02.09.2003, 20:28
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âëàäèìèð ßêîâëåâè÷.
Âû ñ÷èòàåòå ñåáÿ ñïåöèàëèñòîì ïî óðåàïëàçìîçó? Èëè îùóùàåòå ñåáÿ ñòðàñòíûì áîéöîì ñ "ôàðììàôèåé"? Èëè äëÿ èçëå÷åíèÿ îò óðåàïëàçìîçà ãîòîâû ïðåäëîæèòü âàøó ïàíàöåþ è ñâåðöåííóþ èäåþ - îçîíîòåðàïèþ? Èëè ñòîëü îçàáî÷åíû ðîñòîì àíòèáèîòèêîðåçèñòåíòíîñòè ìèêðîîðãàíèçìîâ? Çà÷åì Âû ïóáëèêóåòå ïîäîáíûå ïîñòû? Çàíÿòüñÿ ÷òî ëè áîëüøå íå÷åì? Òàê âàì óæå çäåñü äàâíî ãîâîðÿò. Çàéìèòåñü ðåàëüíûìè êëèíè÷åñêèìè èñïûòàíèÿìè îçîíîòåðàïèè è âíåñèòå ñâîé ïîñèëüíûé âêëàä â äîêàçàòåëüñòâî òîãî, ÷òî ýòà ìåòîäèêà âñå æå íå ÿâëÿåòñÿ ìåäèöèíñêèì øàðëàòàíñòâîì (åñëè ïîëó÷èòñÿ êîíå÷íî).
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 02.09.2003, 21:11
Svetlana_V Svetlana_V âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 27.08.2001
Ãîðîä: Ìîñêâà, ÞÀÎ
Ñîîáùåíèé: 46
Svetlana_V *
Re: Ìîæíî ïðèñîñåäèòüñÿ?

Öèòàòà:
Îïóáëèêîâàíî: Svetlana_V
Ó ìåíÿ â ìàçêå ++++ óðåàïëàçìû, îñòàëüíûõ (ìèêî è õëàìèäèé) - íåò. Â ìàçêå íà ôëîðó ìíîãî ëåéêîöèòîâ.
Îñîáî íè÷åãî íå áåñïîêîèò, ...... Íó, ìîæåò òîëüêî ÷óòü áîëåå ñòðàííûå âûäåëåíèÿ, íî òîëüêî ÷óòü, íå áîëåå.
ß áû ñðîäó íå âçÿëàñü ÷òî-òî â ñåáå èñêàòü, íî ïëàíèðóþ áåðåìåííîñòü, õîòåëîñü áû ïîä÷èñòèòü "õâîñòû".
2 V.Zaitsev:
Ïîëó÷àåòñÿ, ÷òî êëèíè÷åñêèõ ïðîÿâëåíèé îñîáûõ íåò. À êàêèå òàì îñîáûå äîëæíû áûòü ïðîÿâëåíèÿ? Ýòî æ íå ìîëî÷íèöà, íå , òòò, ñèôèëèñ êàêîé-íèòü. Òåì áîëåå, ðàç ôëîðà ýòà ïî÷òè ÷òî óñëîâíî-ïàòîëîãèÿ.

Íó è ++++ (÷åòûðå) - ýòî âðîäå òîæå ïîêàçàòåëü? (ÿ íå ìèêðîáèîëîã, ê ñîæàëåíèþ) Ýòî íå ïðîñòî ôàêò åå ñóùåñòâîâàíèÿ ýòî êîëè÷åñòâåííûé ïîêàçàòåëü (ïîïðàâüòå, ìåäèêè, åñëè ÿ íå ïðàâà).

Íó è òóò æå îòâåò, ïî÷åìó ÿ ëå÷ó ýòó ïî÷òè äðóæåñòâåííóþ èíôåêöèþ - ïëàíèðóþ áåðåìåííîñòü. Îñëîæíåíèé èëè ïóñòûõ ïîïûòîê ìíå ÷òî-òî íå õî÷åòñÿ.
À äàííûå î âëèÿíèè óðåàïëàçìû íà ñïåðìèêîâ èìåþòñÿ. Çà÷åì ñíèæàòü ñâîè è áåç òîãî íåâûñîêèå øàíñû íà áåðåìåííîñòü?

À ÷òî êàñàåòñÿ íàñåëåíèÿ çåìíîãî øàðà... Íó... ÿ äàæ íå çíàþ... Êîëõîç - äåëî äîáðîâîëüíîå. Õîòÿò - ïóñòü ëå÷àòñÿ . Ïîêà ñàìàÿ ñòðàøíàÿ áîëåçíü íà çåìëå - öåëþëèò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 02.09.2003, 21:27
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâ. ïàöèåíòêè, ó êîòîðûõ îáíàðóæåíû óðåàïëàçìû ìåòîäîì ÏÖÐ!
Âî-ïåðâûõ åùå ðàç õî÷ó çàìåòèòü, ÷òî óðåàïëàçìû èçîëèðóþòñÿ ïðèìåðíî ó 50-80% ñåêñóàëüíî àêòèâíûõ æåíùèí è îêîëî 10% ñåêñóàëüíî àêòèâíûõ ìóæ÷èí. êîòîðûå íå èìåþò íèêàêèõ ñèìïòîìîâ è êàêèõ-ëèáî ïðîÿâëÿåíèé èçâåñòíûõ çàáîëåâàíèé.  ñâÿçè ñ ýòèì ïðèíÿòèå ðåøåíèÿ î íåîáõîäèìîñòè "ëå÷åíèÿ" îáíàðóæåííûõ ìåòîäîì ÏÖÐ óðåàïëàçì - âîïðîñ áîëüøå êëèíè÷åñêèé (íàäî õîðîøî çíàòü ïðîÿâëåíèÿ çàáîëåâàíèÿ. êîòîðîå ìîæåò áûòü âûçâàíî óðåàïëàçìàìè) ÷åì ëàáîðàòîðíûé (ïðîñòàÿ ðåàêöèÿ âðà÷à íà ëàáîðàòîðíûé ðåçóëüòàò, òèïà "íàøëè óðåàïëàçìû - íàäî îáÿçàòåëüíî ëå÷èòü"). Âî-âòîðûõ ñëåäóåò ïîíèìàòü. ÷òî íè îäíà èç Ðîññèéñêèõ ÏÖÐ-ëàáîðàòîðèé íå ðàáîòàåò íà ñòàíäàðòíûõ è ñåðòèôèöèðîâàííûõ â ìèðå êîììåð÷åñêèõ ïðàéìåðàõ (êàê áû ðåàêòèâàõ) äëÿ ÏÖÐ ôèðì Roche èëè Dygen. Åñëè áû èñïîëüçîâàëèñü ýòè ñòàíäàðòíûå ïðàéìåðû, äà åùå íà ñîîòâåñòâóþùåì îáîðóäîâàíèè äàííûõ ôèðì, àíàëèç èìåë áû ïðîãíîçèðóåìóþ òî÷íîñòü è ñòîèë áû ïðèìåðíî äîëëàðîâ òàê 50 çà êàæäóþ îïðåäåëÿåìó èíôåêöèþ, ÷òî äëÿ áîëüøèíñòâà Ðîññèÿí äåíüãè â äàííîì ñëó÷àå çàïðåäåëüíûå. òàê ÷òî íàøè ëàáîðàòîðèè èñïîëüçóþò òàê ñêàçàòü "äîìàøíèå çàãîòîâêè", êà÷åñòâî êîòîðûõ äàëåêî íå âî âñåõ ëàáîðàòîðèÿõ îäèíàêîâîþ. ß çíàþ íå ìàëî ëàáîðàòîðèé, êîòîðûå ïðîñòî âûäàþò ðåçóëüòàò ïî çàêàçó äîêòîðà èëè êëèíèêè, êîòîðûå íàïðàâëÿþò ìàòåðèàëû íà èññëåäîâàíèÿ, ÷òî-òî âðîäå "òû õî÷åøü õëàìèäèé? Èõ åñòü ó ìåíÿ!". Òàê ÷òî â íàøèõ óñëîâèÿõ äîñòàòî÷íî íàäåæíûì ìîæíî ñ÷èòàòü àíàëèç, âûïîëíåííûé ëèáî íà ñïåöèôè÷åñêîé êóëüòóðàëüíîé ñðåäå (ïîñòàâëÿåò Sanofi-Pasteur, Ôðàíöèÿ), à åùå ëó÷øå íà ñïåöèôè÷åñêèõ êóëüòóðàëüíûõ ñðåäàõ ëàáîðàòîðèé, êîòîðûå èìåþò ñîáñòâåííûé îïûò èññëåäîâàòåëüñêîé è ïðàêòè÷åñêîé ðàáîòû ñ óðåàïëàçìàìè è åùå æåëàòåëüíî ïðîøëè çàïàäíûé ëàáîðàòîðíûé àóäèò.

Åñëè Âû âñå æå óâåðåíû. ÷òî âàø äîêòîð êâàëèôèöèðîâàí è íå âðåò, à ëàáîðàòîðèÿ íàäåæíà è âûäàåò ñîîòâåñòâóþùèå ðåàëüíîñòè ðåçóëüòàòû. à ó âàñ ïðè ýòîì åñòü ñèìïòîìû îäíîãî èç çàáðîëåâàíèé. êîòîðîå ìîãóò âûçâàòü óðåàïëàçìû, òî èõ ïðàâäà íàäî ëå÷èòü. Âåäü îíè ìîãóò áûòü ïðè÷èíîé ìíîãèõ áîëÿ÷åê îò öåðâèöèòà äî âîñïàëåíèÿ ïðèäàòêîâ (àäíåêñèòà), ìî÷åêàìåííîé áîëåçíè è àðòðèòà, ìîãóò ñòàòü ïðè÷èíîé ïíåâìîíèè íîâîðîæäåííûõ, âçðîñëûõ è äàæå ñåïñèñà ïîñëå àáîðòà. Ëå÷àòñÿ óðåàïëàçìû îäíîé äîçîé â 1,0 ã. àçèòðîìèöèíà (Ñóìàìåä) èëè äîêñèöèêëèíîì 0,1 - 2 ðàçà â äåíü - 7 äíåé. Àëüòåðíàòèâíûå ïðåïàðàòû îòíîñÿòñÿ ê ìàêðîëèäàì è ôòîðõèíîëîíàì.

Ä-ðó Âàä çàìå÷ó, ÷òî ïðè ëå÷åíèè ãåíèòàëüíûõ óðåàïëàçìåííûõ èíôåêöèé àçèòðîìèöèí ïî 0,5 - 2 ðàçà â äåíü íå íàçíà÷àåòñÿ (÷èòàéòå CDC Guidelines ïî ëå÷åíèþ STD [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïðî éîãóðòû â àííàëàõ ìèðîâîé öèâèëèçîâàííîé ìåäèöèíû ÿ, ä-ð Âàä, òîæå íè÷åãî íå ñûñêàë (ìîæåò ïëîõî èñêàë). Ðàâíî êàê è ïðî äèñáàêòåðèîçû (÷òî ýòî âîîáùå òàêîå, îáúÿñíèòå) ïîñëå ñòàíäàðòíûõ êóðñîâ ëå÷åíèÿ STD è ïðî íåîáõîäèìîñòü èõ ëå÷åíèÿ (òåì ïà÷å éîãóðòàìè). Òàê ÷òî ïîðåêîìåíäóéòå ïîæàëóéñòà êàêèå ìàðêè êåôèðîâ è éîãóðòîâ è â êàêèõ òî÷íûõ äîçèðîâêàõ è êóðñàõ Âû ðåêîìåíäóåòå. Êñòàòè, êîãäà äîêëàäûâàåøüñÿ íà ñîëèäíûõ ìåæäóíàðîäíûõ ñèìïîçèóìàõ, ïðîñÿò îãëàñèòü ñ êàêèìè ôàðìêîìïàíèÿìè èìååøü ñâÿçè (÷òîáû ìîæíî áûëî ñóäèòü î ñòåïåíè ïðåäâçÿòîñòè äîêëàäà). Ìîæåò Âû àíãàæèðîâàíû êàêèì-íèáóäü ìîëîêîçàâîäîì, ä-ð Âàä?
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 02.09.2003, 22:43
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Åñòü ëþäè, êîòîðûå î ÷åì áû íè øëà ðå÷ü ñðàçó âñïîìèíàþò îïðåäåëåííóþ íàöèîíàëüíîñòü, à íàø äîñòîïî÷òåííûé Àëåêñåé Âèêòîðîâè÷ – îçîíîòåðàïèþ.
Àëåêñåé Âèêòîðîâè÷, â îòëè÷èå îò Âàñ, ÿ íå áóäó âñåíàðîäíî êâàëèôèöèðîâàòü ïîäîáíóþ ìàíèþ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 03.09.2003, 00:02
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Ñâåòëàíà!
ß ëèøü îòìåòèë, ÷òî òàêîå ëå÷åíèå òàê æå ìîæåò áûòü äëÿ îðãàíèçìà íåáåçîáèäíî è äàëåêî íå âñåãäà ïðèâîäèò ê ðåçóëüòàòó, ê êîòîðîìó ñòðåìèòåñü. Ïîýòîìó, íà âñÿêèé ñëó÷àé, åãî ïðîâîäèòü íå ñòîèò. Äîâåðÿåòå ëå÷àùåìó âðà÷ó, ïîëàãàåòå, ÷òî Âàì íàäî ïðîëå÷èòñÿ - íåò âîïðîñîâ. Õîòÿ ÿ íà Âàøåì ìåñòå, ñäåëàë áû áàê. ïîñåâ íà ÷óâñòâèòåëüíîñòü, à íå ëå÷èëñÿ áû ñðàçó íåñêîëüêèìè àíòèáèîòèêàìè. Íà îñíîâàíèè êàêîãî àíàëèçà îïðåäåëåíà óðåàïëàçìà ++++?
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 03.09.2003, 09:19
Svetlana_V Svetlana_V âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 27.08.2001
Ãîðîä: Ìîñêâà, ÞÀÎ
Ñîîáùåíèé: 46
Svetlana_V *
Äîáðîå óòðî


V. ZAITSEV
ß ëèøü îòìåòèë, ÷òî òàêîå ëå÷åíèå òàê æå ìîæåò áûòü äëÿ îðãàíèçìà íåáåçîáèäíî è äàëåêî íå âñåãäà ïðèâîäèò ê ðåçóëüòàòó, ê êîòîðîìó ñòðåìèòåñü
Íó è ïóñòü Ïî êðéíåé ìåðå ÿ áóäó çíàòü, ÷òî ñäåëàëà ïî÷òè âñå âîçìîæíîå èç òîãî, ÷åì ðàñïîëàãàåò ñîâðåìåííàÿ ìåäèöèíà. Ñäåëàòü âñ¸ âîçìîæíîå - óâû, íå õâàòèò íè ñðåäñòâ íè ñèë.

Õîòÿ ÿ íà Âàøåì ìåñòå, ñäåëàë áû áàê. ïîñåâ íà ÷óâñòâèòåëüíîñòü, à íå ëå÷èëñÿ áû ñðàçó íåñêîëüêèìè àíòèáèîòèêàìè
Îê, áóäåì ëå÷èòüñÿ îäíèì.
À áàê-ïîñåâ ïðåäëàãàòü âðà÷ó - òîæå íå ó êàæäîãî ÿçûê ïîâåðíåòñÿ. Íèêòî íå õî÷åò â äàëüíåéøåì ê ñåáå îòíîøåíèÿ êàê ê ïàöèåíòó-"óìíèêó". È òàê áîëå-ìåíåå íîðìàëüíîãî âðà÷à íàéòè - öåëîå ñîáûòèå.

Íà îñíîâàíèè êàêîãî àíàëèçà îïðåäåëåíà óðåàïëàçìà ++++?
Íå çíàþ Ó ìåíÿ èõ ùàñ íà ðóêàõ íåò - ïîäøèëè ê äåëó.
Áûëî íàçíà÷åíî 2 ìàçêà:
1 - "íà ôëîðó"
2 - íà òð¸õ âîçáóäèòåëåé: óðåàïëàçìó, õëàìèäèè, ìèêîïëàçìó ãåíèòàëüíóþ.
Ýòî áûë íå áüàê-ïîñåâ, ÿ óæå ïèñàëà âûøå (íèæå?), àíàëèç äåëàëè çà äâà äíÿ, çà 2 äíÿ íè÷åãî íå óñïååò âûðàñòè. Çíà÷èò áûëî ÏÖÐ èëè ÷òî òàì òåïåðü äåëàþò...

Ïðè÷åì - àíàëèç ÿ äåëàëà â ýòîé êëèíèêå áóäó÷è åùå "÷åëîâåêîì ñ óëèöû". ß íå íàáëþäàëàñü ó íèõ, ÿ ïðèíåñëà íàïðàâëåíèå, âûïèñàííîå âðà÷îì èç ÖÏÑèÐ, õîòÿ ñåñòðà åãî òîëêîì è íå âèäåëà. Êîðî÷å, ÷òî ÿ õî÷ó ñêàçàòü - ÷òî îíè íå áûëè çàèíòåðåñîâàíû íàõîäèòü ó ìåíÿ ÷òî-òî. È óæ åñëè áûëè áû ïðèïèñàíû ìíå ýòè 4+, òòî íàâåðíîå íå â òàêîé íàãëîé ôîðìå Õâàòèëî áû è äâóõ +.
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 03.09.2003, 10:58
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Ñâåòëàíà!
Àíàëèç ñ ïîìîùüþ ÏÖÐ òîæå ìîæåò áûòü ïîëóêîëè÷åñòâåííûì, íî òàê ëè ýòî â Âàøåì ñëó÷àå, åñòü ñîìíåíèÿ. Ìíå íåìíîãî ñòðàííî, ÷òî Âû òàêàÿ ñìåëàÿ íà ôîðóìå, áîèòåñü ïîãîâîðèòü ñ ëå÷àùèì âðà÷îì. Ëå÷åíèå íàâñêèäêó îäíèì èç ïðåäëîæåííûõ Âàì àíòèáèîòèêîâ íå ëó÷øèé âàðèàíò.  êîíöå êîíöîâ, ýòî æå Âàøå çäîðîâüå è Âû çà ëå÷åíèå ïëàòèòå. À ïðè íåàäåêâàòíîé ðåàêöèè âðà÷à íàéäåòå äðóãîãî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 03.09.2003, 11:45
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,746
Ïîáëàãîäàðèëè 33,409 ðàç(à) çà 31,754 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé äîêòîð Àëåêñåé Æèâîâ!
Ðåêîìåíäàöèè ïî äîçå àçèòðîìèöèíà áûëè âçÿòû íà îñíîâàíèè ñòàòüè è ñ ó÷åòîì, ÷òî äëèòåëüíîñòü èíôèöèðîâàíèÿ ó ïàöèåíòêè áûëà âñå æå áîëåå 3 íåäåëü (õîòÿ è ñîãëàñåí, ÷òî ýòî íå îäíî è òîæå, ÷òî 3-íåäåëüíîå íàëè÷èå ñèìïòîìàòèêè):

Drugs Exp Clin Res. 2001;27(4):135-9.
Azithromycin and doxycycline in the treatment of female patients with acute urethral syndrome caused by Ureaplasma urealyticum: significance of duration of clinical symptoms.

Skerk V, Schonwald S, Krhen I, Rusinovic M, Strapac Z, Vukovic J.

One hundred ninety-two female patients with acute urethral syndrome caused by Ureaplasma urealyticum were examined. First, patients were divided into two groups: those with clinical symptoms present for less than 3 weeks before the start of treatment and those with clinical symptoms 3 weeks or longer before the beginning of therapy. The patients were then further divided into groups and randomized to receive azithromycin once daily in a single dose of 1 g or 500 mg once daily for 6 days, or to receive doxycycline 100 mg b.i.d. for 14 days or 100 mg b.i.d. for 7 days (eight study groups in all). Clinical and bacteriological efficacy were evaluated 3 weeks after the end of therapy. In the group of patients with disease symptoms lasting for 3 weeks or longer, eradication and clinical cure rates were significantly higher after the administration of azithromycin at a dose of 1 x 500 mg/6 days than after a single dose of 1 g (p < 0.001).

Î èîãóðòàõ è íå òîëüêî ïðè ïîëîâûõ èíôåêöèÿõ:

Obstet Gynecol Surv. 2003 May;58(5):351-8.
Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: a systematic review.
Van Kessel K, Assefi N, Marrazzo J, Eckert L.
Department of Obstetrics & Gynecology, University of Washington, Harborview Medical Center, Seattle, Washington 98104, USA. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

...Lactobacillus recolonization (via yogurt or capsules) shows promise for the treatment of both yeast vaginitis and bacterial vaginosis with little potential for harm...

Òê íå ÿâëÿþñü äèñòðèáüþòîðîì èëè ïðîìîòîðîì ê-ëèáî ìîëîêîçàâîäà â Ðîññèè, à òàêæå íå çíàêîì ñ Ðîññèéñêîé ìîëî÷íîé èíäóñòðèåé, ïîýòîìó ïðîñòî ðåêîìåíäóþ èîãóðòû ñ æèâûìè ëàêòî èëè æå áèôèäî-áàêòåðèÿìè èëè æå êàïñóëüíûå ïðåïàðàòû ñ æèâûìè êóëüòóðàìè. (ðåêîìåíäàòåëüíûé õàðàêòåð, íå òðåáóåò îáÿçàòåëüíîãî èñïîëíåíèÿ).

×òî òàêîå àíòèáèîòèê-àññîöèèðîâàííàÿ äèàðåÿ (ïî÷åìó-òî äîêòîðà ó íàñ åå íàçûâàþò äèñáàêòåðèîçîì) è êàê åå ìîæíî ëå÷èòü/ïðåäóïðåæäàòü çäåñü èëè äð. àíàëîãè÷íûå îáó÷àþùèå îáçîðû (tutorials)
Int J Antimicrob Agents. 2000 Dec;16(4):521-6.
Treatment and prevention of antibiotic associated diarrhea.

Bergogne-Berezin E.

Microbiology Department, University Paris 7, 100 bis rue du Cherche-Midi, 75006 Paris, France. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Mild or severe episodes of antibiotic-associated diarrhea (AAD) are common side effects of antibiotic therapy. The incidence of AAD differs with the antibiotic and varies from 5 to 25%. The major form of intestinal disorders is the pseudomembranous colitis associated with Clostridium difficile which occurs in 10-20% of all AAD. In most cases of AAD discontinuation or replacement of the inciting antibiotic by another drug with lower AAD risk can be effective. For more severe cases involving C. difficile, the treatment of diarrhea requires an antibiotic treatment, with glycopeptides (vancomycin) or metronidazole. Another approach to AAD treatment or prevention is based on the use of non-pathogenic living organisms, capable of re-establishing the equilibrium of the intestinal ecosystem. Several organisms have been used in treatment or prophylaxis of AAD such as selected strains of Lactobacillus acidophilus, L. bulgaricus, Bifidobacterium longum, and Enterococcus faecium. Another biotherapeutic agent, a non-pathogenic yeast, Saccharomyces boulardii has been used. In animal models of C. difficile colitis initiated by clindamycin, animals treated with S. boulardii (at end of vancomycin therapy) had a significant decrease in C. difficile colony-forming units, and of toxin B production. In several clinical randomised trials (versus placebo), S. boulardii has demonstrated its effectiveness by decreasing significantly the occurrence of C. difficile colitis and preventing the pathogenic effects of toxins A and B of C. difficile. It has been shown to be a safe and effective therapy in relapses of C. difficile colitis. A good response has been seen in children with AAD, treated by S. boulardii only. In ICUs prevention of AAD remains based on limitation of antibiotic overuse and spread of C. difficile or other agents of AAD should be prevented by improved hygiene measures (single rooms, private bathrooms for patients, use of gloves and hand washing for personnel). In addition the increasing use of biotherapeutic agents such as S. boulardii should permit the prevention of the major side effect of antibiotics, i.e. AAD in at risk patients.

Clin Infect Dis. 1998 Oct;27(4):702-10.
Mechanisms and management of antibiotic-associated diarrhea.
Hogenauer C, Hammer HF, Krejs GJ, Reisinger EC.

Am J Gastroenterol. 2000 Jan;95(1 Suppl):S11-3.
The effect of probiotics on Clostridium difficile diarrhea.
Pochapin M.
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 03.09.2003, 11:55
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,746
Ïîáëàãîäàðèëè 33,409 ðàç(à) çà 31,754 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äëÿ Ñâåòëàíû:
Íåêîòîðûå ïóáëèêàöèè î íåîáõîäèìîñòè ýðàäèêàöèè óðåàïëàçìû ïåðåä áåðåìåííîñòüþ/ âî âðåìÿ áåðåìåííîñòè è íåêîòîðîé ìàëîýôôåêòèâíîñòè 1 ã òåðàïèè àçèòðîìèöèíîì:

Zhonghua Liu Xing Bing Xue Za Zhi. 2001 Aug;22(4):293-5.
[Clinic intervention study on urogenital mycoplasma infection of pregnant women]
[Article in Chinese]
Ye Y, Tu S, Li H.
Tongji Hospital, Tongji University, Shanghai, 200065, China.
OBJECTIVE: To explore the hypothesis of pathogenic relationship between urogenital mycoplasma infection and adverse perinatal outcomes. METHODS: Four hundred and eighty-eight mycoplasma-positive pregnant women detected by culture method were randomly divided into erythromycine-intervention group and non-intervention group. Comparison was made on rate of reverse sero-conversion, of vertical transmission to mycoplasma and adverse perinatal outcomes incidence between groups. RESULTS: Ureaplasma urealyticum sero-conversion rate and rate of vertical-transmission in intervention group were significantly lower than in non-intervention group (P < 0.05). The incidences rates of preturm labor, post partum fever, puerperal infection and neonate pneumonia in intervention group were significantly lower than in non-intervention group (P < 0.05). CONCLUSION: Erythromycin is effective in control of ureaplasma urealyticum infection among pregnant women through cutting off vertical transmission passway and lowering adverse perinatal outcomes against ureaplasma urealyticum.

J Matern Fetal Med. 1999 Jan-Feb;8(1):12-6.
Efficacy of azithromycin in reducing lower genital Ureaplasma urealyticum colonization in women at risk for preterm delivery.
Ogasawara KK, Goodwin TM.
Department of Obstetrics and Gynecology, University of Southern California, School of Medicine, Women's and Children's Hospital, Los Angeles, USA. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
OBJECTIVE: The purpose of this study was to determine if azithromycin is effective in reducing lower genital colonization of Ureaplasma urealyticum in women with preterm labor or preterm premature rupture of membranes (PROM). METHODS: A randomized, double-blinded, placebo-controlled prospective study of 60 pregnancies was carried out between 22 and 34 weeks. Genital mycoplasma cultures were performed at the time of admission. Patients were randomized to receive either a single dose of azithromycin (four 250 mg capsules) or a placebo in addition to prophylactic intravenous ampicillin. Repeat cultures were done on undelivered patients 7 days after enrollment. The study had power to detect a 50% decrease in colonization. RESULTS: Overall, lower genital colonization was 47/59 (79.7%) for U. urealyticum. Seven days after enrollment, U. urealyticum was isolated in 14/15 (93.3%) of the azithromycin-treated cases and in 11/14 (78.6%) of the controls (RR = 1.19, 95% CI = 0.88-1.61). Vertical transmission of U. urealyticum was 3/15 (20%) in the azithromycin-treated cases and 5/10 (50%) for the controls (RR = 0.40, 95%, CI = 0.12-1.31). CONCLUSION: These data suggests that a single 1 g dose of azithromycin is ineffective in reducing lower genital colonization with U. urealyticum.
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 03.09.2003, 12:14
mina mina âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.03.2003
Ñîîáùåíèé: 82
mina *
Ïðîëå÷èëàñü 5 äíåé ñóìàìåäîì (1 ã ïåðâûé äåíü, îñòàëüíûå ïî 500 â äåíü, áûëà äèàðåÿ), òåïåðü óæå 8 äíåé ïüþ îôëîêñèí 200 õ 2 ðàçà â äåíü, ñèìïòîìû öèñòèòà, ææåíèÿ ñîõðàíÿþòñÿ, äîáàâèëè öèêëîôåðîí, æåíüøåíåâûé ÷àé, íèñòàòèí, ìèðàìèñòèíîâûå òàìïîíû íà 2 ÷àñà, 5 íîê, ôèòîëèçèí. Ìîæåò, åùå ÷òî-íèáóäü íàäî? Óæå âòîðîé ðàç ëå÷óñü... Èëè ïðîäëèòü îôëîêñèí äíåé äî 14? Ó ìåíÿ ê íåìó ïî áàêïîñåâó (íå êîíêðåòíî óðåàïëàçìû, à âîîáùå ôëîðû) âðîäå ÷óâñòâèòåëüíîñòü
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 03.09.2003, 14:27
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñîîáùåíèå mina ïîäòâåðæäàåò òîò ôàêò, ÷òî ñóìàìåä íàäî èñïîëüçîâàòü â ðåêìîåíäîâàííûõ äîçàõ. Êàê ïðàâèëî â ýòîì ñëó÷àå ïðîáëåì ñî ñòóëîì íå áûâàåò. Äà è èìåâøàÿ ìåñòî íå äëèòåëüíàÿ äèàðåÿ âîâñå íå îçíà÷àåò êàêèõ-ëèáî çíà÷èìûõ ïðîáëåì. Ñðàçó îãîâîðþñü äëÿ òåõ. êòî îòñòàèâàå ñóùåñòâîâàíèÿ êëèíè÷åñêîé äåôèíèöèè "äèñáàêòåðèîç". Äåëî âåäü íå â òîì, ÷òî êàêèõ-ëèáî èçìåíåíèé ìèêðîôëîðû êèøå÷íèêà âîâñå íå áûâàåò (èëè äèñáàêòåðèîçà âîâñå íå áûâàåò) ïîñëå ïðèåìà àíòèáèîòèêîâ. Äåëî â òîì, ÷òî è òåðìèí äèñáàêòåðèîç (ðàâíî êàê è äèñáèîç) íå ãîâîðèò ðîâíûì ñ÷åòîì íå î ÷åì (ñëèøêîì ðàçìûòîå ïîíÿòèå), è êëèíè÷åñêàÿ çíà÷èìîñòü (îïàñíîñòü äëÿ çäîðîâüÿ ÷åëîâåêà) ýòîãî ìàëîïîíÿòíîãî è ìàëîîïðåäåëåííîãî ñîñòîÿíèÿ íå ÿñíà, à ñëåäîâàòåëüíî íå ÿñíî ÷òî ñ ýòèì áåç ÷åòêèõ êðèòåðèåâ ÿâëåíèåì íàäî âëîîáùå äåëàòü (ïðèìåíÿòü îçîí ìîæíî âñåãäà êîíå÷íî è ïðè âñåõ îáñòîÿòåëüñòâàõ îí "îäíîçíà÷íî ïîëåçåí", íî ÿ èìåþ ââèäó ìåäèöèíñêèå, à íå øàðëàòàíñêèå âîçäåéñòâèÿ). Òåïåðü ïî ñóòè ñîîáùåíèÿ minaþ Öèñòèò ìîæåò áûòü è ÷àùå âñåãî ñîâåðøåííî íå ñâÿçàí ñ èíôåêöèÿìè, ïåðåäàâàåìûìè ïîëîâûì ïóòåì. Åñëè îôëîêñèí çà 2-3 äíÿ â äàííîé äîçå ñèìïòîìû öèñòèòà íå ëèêâèäèðîâàë, íàäî ïðîâîäèòü äîïîëíèòåëüíûå òåñòû (ïîñåâ ìî÷è íà ìèêðîôëîðó, â ò.÷. ãðèáêè, âîçìîæíî íåîáõîäèìî ïîëíîå óðîëîãè÷åñêîå îáñëåäîâàíèå âêëþ÷àÿ ÓÇÈ ïî÷åê, ìî÷åâîãî ïóçûðÿ. öèñòîñêîïèþ è ò.ä.äëÿ îïðåäåëåíèÿ ôàêòîðîâ, ñïîñîáñòâóþùèõ õðîíèçàöèè èíôåêöèé ìî÷åâûõ ïóòåé). Ýôôåêòèâíîñòü öèêëîôåðîíà ïðè êàêèõ-ëèáî çàáîëåâàíèÿõ ÷åëîâåêà íå äîêàçàíà. Ýòî â åùå áîëüøåé ñòåïåíè îòíîñèòñÿ ê æåíüøåíåâîìó ÷àþ. õîòÿ ýòî (â îòëè÷èå îò öèêëîôåðîíà) ñêîðåå ïðèÿòíî, ÷åì âðåäíî. Òî, ÷òî ôèòîëèçèí êàê òî ðàáîòàåò ïðè èíôåêöèÿõ ìî÷åâûõ ïóòåé íèêòî íå äîêàçàë. Íèòðîêñîëèí (5 ÍÎÊ) óæå äàâíî çàáûò â öèâèëèçîâàííûõ ñòðàíàõ, ò.ê. íå ðàáîòàåò â îòíîøåíèè áîëüøèíñòâà èíôåêöèé ìî÷åâûõ ïóòåé. Íèñòàòèí óæå äàâíî íà ïîìîéêå ñîâðåìåííîé ìåäèöèíû, ò.ê. ïî÷òè íå âñàñûâàåòñÿ èç êèøå÷íèêà è ê íåìó óñòîé÷èâî äî 50% êëèíè÷åñêè èçîëèðóåìûõ øòàìîâ ãðáîâ ðîäà êàíäèäà. Ìèðàìèñòèíîâûå òàìïîíû - ïðîñòî êîíöëàãåðü. Íàäî ïîñîâåòîâàòü ãèíåêîëîãó ïîâñòàâëÿòü èõ ñåáå ñàìîé (ñàìîìó). Ñîâåòóþ âàì íàéòè ãðàìîòíîãî äîêòîðà mina.

Óâ. ä-ð Âàä. Äåëî â òîì, ÷òî ïîêà èññëåäîâàíèÿ îòíîñèòåëüíî êåôèðîâ è éîãóðòîâ è èõ âîçìîæíîãî ïîçèòèâíîãî âëèÿíèÿ íà ëþáóþ ìèêðîôëîðó ÷åëîâåêà, à òàêæå íåîáõîäèìîñòè îáÿçàòåëüíîãî ïðèìåíåíèÿ âìåñòå/ñðàçó ïîñëå àíòèáèîòèêîâ - íàõîäÿòñÿ â ïèëîòíî-çà÷àòî÷íîì ñîñòîÿíèè è íàõîäÿòñÿ íà óðîâíå ìíåíèé îòäåëüíûõ àâòîðîâ.  ñòàíäàðòû ëå÷åíèÿ ê.ë. çàáîëåâàíèé éîãóðòû íå âõîäÿò. Íåÿñíî íå òîëüêî èõ ïîçèòèâíîå äåéñòâèå, íî è âçàèìîäåéñòâèå ñ îäíîâðåìåííî ïðèíèìàåìûìè àíòèáèîòèêàìè.  ñâÿçè ñ ýòèì è ïîòîìó, êîãäà Âû êîìó-ëèáî èõ íàçíà÷åòå â êà÷åñòâå ëå÷åíèÿ, íàäî áû ïðåäóïðåæäàòü, ÷òî ýòî íåêèé ýêñïåðèìåíòàëüíûé ïîäõîä è Âàøå ëè÷íîå ìíåíèå, òîëüêî è âñåãî. À CDC Guidelines Âû âñå æå ïî÷èòàéòå, óâ. ä-ð Âàä. Îíè äîñòàòî÷íî ñâåæèå è ïðî éîãóðòû òàì íè ñëîâà.

P.S. Ýòî ïðàâäà, ÷òî â ïîñëåäíèå ãîäû ðàñòåò ðåçèñòåíòíîñòü óðåàïëàçì ê ìàêðîëèäàì.  ñëó÷àå íàëè÷èÿ ðåçèñòåíòíûõ øòàìîâ - ïðàâ Âëàäèìèð ßêîâëåâè÷, íàäî îïðåäåëèòü ÷óâñòâèòåëüíîñòü óðåàïëàçì ê àíòèáèîòèêàì. Òîëüêî äëÿ ýòîãî íóæíà õîðîøàÿ ëàáîðàòîðèÿ, êîòîðûõ â Ðîññèè êðàéíå ìàëî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #27  
Ñòàðûé 03.09.2003, 15:29
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,746
Ïîáëàãîäàðèëè 33,409 ðàç(à) çà 31,754 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñïàñèáî çà îáñòîÿòåëüíûé îòâåò, óâàæàåìûé Àëåêñåé Æèâîâ, ÷èòàòü ïîäðîáíî ýòè äà è äð. ïîõîæèå (íàïð. åâðîïåéñêèå) guidelines âðåìåíè íåò, òê ñîâñåì íèêàê íå îòíîñèòñÿ ê ìîåìó ïðîôèëþ ðàáîòû. Âñå îíè íîñÿò ðåêîìåíäàòåëüíûé õàðàêòåð è íå îáÿçàòåëüíû ê ñòðîãîìó èñïîëíåíèþ, ïî êðàéíåé ìåðå çà ïðåäåëàìè ÑØÀ. Òàêæå êàê è âñå ìîè ñîîáùåíèÿ íîñÿò ÷èñòî ðåêîìåíäàòåëüíûé õàðàêòåð, îñíîâàííûé ÷àùå âñåãî íà îñíîâàíèè çàðóáåæíûõ ïóáëèêàöèé, òå îïûòà êîëëåã. Èõ îïûò ïðèìåíåíèÿ èîãóðòîâ èëè ïðîáèîòèêîâ â êàïñóëàõ â ëå÷åíèè çàáîëåâàíèé ÿâëÿåòñÿ ëèøü ïîëîæèòåëüíûì ïðèìåðîì èñïîëüçîâàíèÿ è ìîæåò ñòàòü âàðèàíòîì ëå÷åíèÿ, à íå ÿâëÿåòñÿ ñòðîãèì ïðèêàçîì ê äåéñòâèþ.
Íàçíà÷àòü ëå÷åíèå (â òîì ñìûñëå, êàêîé Âû åãî âêëàäûâàåòå â ýòî ïîíÿòèå, íàïð. áóäó÷è âðà÷åì íà ïðèåìå â àìáóëàòîðèè/ñòàöèîíàðå) íå âèäÿ ïàöèåíòà è áåç äð. êëèí. ïîäõîäîâ ê îáñëåäîâàíèþ âèðòóàëüíî íå èìåþ íèêàêîãî ìîðàëüíîãî ïðàâà, ïîýòîìó âñå "âèðòóàëüíûå" ðåêîìåíäàöèè èìåþò ïðåäïîëîæèòåëüíûé îòòåíîê íà íà ëè÷íîå óñìîòðåíèå ïàöèåíòà èëè æå åãî äîêòîðà ïðèíèìàòü èõ ê ñâåäåíèþ èëè íåò. Ïîýòîìó íèêàêèõ ïðåäóïðåæäåíèé î ñóùåñòâîâàíèè òîãî èëè èíîãî âèäà òåðàïèè èëè äèàãí. ïîäõîäîâ è íå äåëàþ.
Ïîýòîìó çà Âàìè îñòàâëÿþ ïðàâî âûíîñèòü ñâîå èíîå ìíåíèå ïî ëþáîìó âîïðîñó, äèñêóòèðóåìîìó íà ôîðóìå, ïðîñüáà ëèøü äåëàòü ýòî êîððåêòíî ïî îòíîøåíèþ ê êîëëåãàì, äàáû â ïîãîíå çà ïîèñêîì èñòèíû íå ïðåñòóïàòü ãðàíèöû âðà÷åáíîé è êîëëåãèàëüíîé ýòèêè è äåîíòîëîãèè. Âàøè èðîíè÷íûå âûñêàçûâàíèÿ íà ñâîé àäðåñ ñ óäîâîëüñòâèåì ïðèìó íà ëè÷íûé ìåéë (áëàãî îí ó Âàñ åñòü), à íà ôîðóìå äëÿ ïàöèåíòîâ óæ ïîïûòàéòåñü áûòü ïîñäåðæàííåå. Îïÿòü-òàêè âñå ïðåòåíçèè ê ìíåíèÿì àâòîðîâ è ñïåöèàëèñòîâ, ìíîé öèòèðóåìûõ, ïîæàëóéñòà àäðåñóéòå ëè÷íî (äëÿ ýòîãî ñïåöèàëüíî â ìåä.æóðíàëàõ ñóùåñòâóþò ðàçäåëû: ïèñüìà ê èçäàòåëþ èëè êîììåíòàðèè).
Èñêðåííå, Âàäèì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #28  
Ñòàðûé 03.09.2003, 16:22
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,746
Ïîáëàãîäàðèëè 33,409 ðàç(à) çà 31,754 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Ìèíà!
 ñâÿçè î îáèëüíûì ïîÿâëåíèåì êîíñóëüòàíòîâ, ïîçâîëüòå îñòîðîæíî ïðåäïîëîæèòü, ÷òî åñëè öèñòèò ó âàñ îáóñëîâëåí âñå-òàêè óðåàïëàçìîé, òî ñóùåñòâóåò ðàçíèöà â àíòèóðåàïëàçìåííîì äåéñòâèè îôëîêñàöèíà (Òàðèâèäà) è æåëàòåëüíî íå òîëüêî çíàòü àíòèáèîòèêî-÷óâñòâèòåëüíîñòü, íî è ìèêðîáèöèäíóþ êîíöåíòðàöèþ äëÿ ïîäáîðà äîçû: òàê Òàðèâèä â êîíöåíòðàöèè 0,8 ìêã/ìë ïîäàâëÿåò 50% ðîñòà óðåàïëàçì, â òî âðåìÿ êàê äëÿ 90% ïîäàâëåíèÿ íåîáõîäèìî ïîääåðæàíèå 3,1 ìêã/ìë: ìàêñ. ïîäüåì ÷åðåç 1 ÷àñ â ïëàçìå ïîñëå 0,2 - 3,2 ìêã/ìë, ïîñëå 0,4 - 5,3 ìêã/ìë. Ïîýòîìó ñêîðåå ñëåäóåò äóìàòü î ïîâûøåíèè äîçû ïðåïàðàòà, íåæåëè óäëèíåíèÿ öèêëà ëå÷åíèÿ. Êðîìå òîãî, âîçìîæíî Âàø öèñòèò íå ñâÿçàí ñ èíôåêöèåé è Âàì ïîíàäîáÿòñÿ äîï. îáñëåäîâàíèÿ, î êîòîðîì óïîìèíàë ä-ð Æèâîâ èëè æå óêàçàííûå â ïðåäûäóùèõ ïîñòèíãàõ ìîè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #29  
Ñòàðûé 03.09.2003, 18:32
mina mina âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.03.2003
Ñîîáùåíèé: 82
mina *
Ïîâûøó äîçó îôëîêñèíà äî 600 èëè 800 â äåíü, òàê õî÷åòñÿ âûëå÷èòüñÿ ñêîðåå, áüþñü-áüþñü. [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì]

Íå çíàþ, êóäà ìíå áåæàòü â ìîåì ãîðîäå Ðîñòîâå-íà-Äîíó çà õîðîøèì ãèíåêîëîãîì èëè óðîëîãîì, è òàê âðîäå â ìåäèíñòèòóòå ëå÷óñü [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] - ìîæåò, â âåíäèñïàíñåð???

À ìîæåò, îôëîêñèí ïîääåëüíûé - â÷åðà, íàïðèìåð, îáíàðóæèëà, ÷òî öèêëîôåðîí ïîääåëüíûé êóïèëà - â èíñòðóêöèè îøèáêè îðôîãðàôè÷åñêèå è ïðè ñðàâíåíèè óïàêîâêè âèäíà ðàçíèöà. Ïîéäó êóïëþ ðóññêèé îôëîêñàöèí, ìîæåò, ïîäåøåâëå íå áóäóò ïîääåëûâàòü? Ïîíèìàþ, ÷òî íèêàêîé ãàðàíòèè.

CDC guidlines ÿ ïî÷èòàëà - òîò æå îôëîêñàöèí èëè ýðèòðîìèöèí, òàê ÷òî íå çíàþ, ÷òî è äåëàòü, ïîéäó òåïåðü ê óðîëîãó
Îòâåòèòü ñ öèòèðîâàíèåì
  #30  
Ñòàðûé 03.09.2003, 20:58
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâ. Âàäèì,
Ñêàæèòå, à Âû òî÷íî çíàåòå êîãäà è çà÷åì íàäî íàçíà÷àòü éîãóðòû? Âàì äîïîäëèííî (òàêæå êàê è äëÿ îôëîêñàöèíà) èçâåñòíû äîçèðîâêè ýòèõ éîãóðòîâ? Âû àáñîëþòíî óâåðåíû, ÷òî âñÿêèé ðàç èõ íåîáõîäèìî ïðèìåíÿòü ïîñëå àíòèáèîòèêîòåðàïèè? Âû çíàåòå êàê âçàèìîäåéñòâóþò ýòè ñàìûå éîãóðòû ñ ê.ë. ëåêàðñòâàìè? Âåäü Âû æå íå õóæå ìåíÿ íàäåþñü ïîíèìàåòå, ÷òî ýòè âîïðîñû äëÿ éîãóðòîâ åùå íå îòâå÷åíû, à ñòàíäàðòèçèðîâàííî íàçíà÷àòü éîãóðòû íåâîçìîæíî. Âîò â Âàøåì âðà÷åáíîì îôèñå îäèí íà îäèí, ãäå ó Âàñ åñòü âðåìÿ è âîçìîæíîñòü îáúÿñíèòü ñâîþ ïîçèöèþ áîëüíîìó ñ ãëàçó íà ãëàç - ïîæàëóéñòà õîòü éîãóðòû, õîòü êåðîñèíîâûå ïðèìî÷êè. Äåëî èíäèâèäóàëüíîãî âêóñà è ñîñáòâåííîé âðà÷åáíîé ñîâåñòè, âçàèìîîòíîøåíèé ñ ïàöèåíòîì. íàêîíåö. À âîò â èíåòå òî êàê ðàç íàäî áûòü î÷åíü îñòîðîæíûì. Çäåñü íàâðåäèòü òåì, ÷òî íå âõîäèò â òåêñòû (ñòàíäàðòû), êîòîðûå Âàì ñêó÷íî ÷èòàòü, î÷åíü ëåãêî. Èìåííî ïîýòîìó ÿ è ïðîñèë Âàñ âìåñòå ñ éîãóðòîâûìè ðåêîìåíäàöèÿìè ïèñàòü, ÷òî ýòî Âàøå ÷àñòíîå ìíåíèå, à éîãóðòîòåðàïèÿ íå ÿâëÿåòñÿ ïîêà îáùåïðèíÿòîé (ýòî ïîìèëóé Áîã íå çíà÷èò, ÷òî îíà íåýôôåêòèâíà). Òîëüêî è âñåãî. Ïèñàòü Âàì íà èìåéë î Âàøèõ ñ ìîåé òî÷êè çðåíèÿ íå ñîâñåì êîððåêòíûõ ðåêîìåíäàöèÿõ îïÿòü æå íà ìîé âçãëÿä íå èìååò ñìûñëà. ß ñ÷èòàþ, ÷òî ìîè êðèòè÷åñêèå çàìå÷àíèÿ ïî éîãóðòàì êàê ðàç ïðåäíàçíà÷åíû äëÿ øèðîêîãî êðóãà ÷èòàòåëåé, â ò.÷. âðà÷åé. Åñëè ÿ Âàñ ëè÷íî ÷åì òî îáèäåë, ïðîñòèòå.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 09:49.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.